Opinion: Tinengotinib Shows Promise for Cholangiocarcinoma After FGFR Inhibitor Treatment
Oncology nurses can advocate for patients with cholangiocarcinoma to participate in on-going clinical trials with tinengotinib.
ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment
Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.
Repotrectinib Receives Priority Review From FDA for NTRK+ Solid Tumors
A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.
Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium
In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.
Virtual Reality Is a Tool for Education, Relaxation for Nurses and Patients
Virtual reality headsets can be used to reduce anxiety in patients with cancer undergoing treatment and as an educational tool for nurses learning how to have difficult conversations with patients.
T-Cell Engagers Take Center Stage in Large B-Cell Lymphoma
Bispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Immune Engager Therapies Improve Responses, PFS in RRMM After CAR T-Cell Therapy
Liso-Cel Elicits Rapid, Durable Responses in Relapsed/Refractory CLL/SLL
Adding Azoles May Not Impact Efficacy of Ruxolitinib in Acute GVHD Treatment
Ruxolitinib Plus Belumosudil Confers a 55% Response Rate in GVHD
2 Commerce Drive Cranbury, NJ 08512